

Hot Topics: What to Expect at the Upcoming RAD, ReV, and RAA Conferences!

Lois Levine, MA

It's now only a couple of weeks until the annual Revolutionizing Atopic Dermatitis (RAD) conference, and this year promises to be even more exciting with the addition of 2 inaugural conferences: Revolutionizing Vitiligo (ReV) and Revolutionizing Alopecia Areata (RAA). Here is what some of the presenters have to say about their don't miss-sessions:

Raj Chovatiya, MD, PhD, MSCI, who will be presenting, "How do Approved Therapies Stack Up?" at **RAD**, had this to say: "When it comes to our many approved targeted therapies for AD, we have to remember that "clear/almost clear" or "EASI-75" aren't everything. After all, itch is the key and central symptom in AD. How exactly do the approved therapies stack up in terms of itch improvement? The lecture will provide a crash course on the numbers you need to know."

For his session, "Can we Achieve Remission With our Current Therapies?" Chovatiya adds, "Everyone wants to say the "R" word these days when it comes to AD— remission. The big question on everyone's minds: is it possible with our emerging therapies? To answer that question, instead of looking into the future, we need to first understand the present. Join us as we take a look at the *now* and see where current therapies stand with long-term improvement of AD signs and symptoms."

At **ReV**, don't miss the breakfast with **Caroline Le Poole, PhD**, who will be presenting her keynote on "The Microbiome in Vitiligo." "Food for thought," says Dr. Le Poole. "We now know that T cells attack melanocytes in the basal layer of the skin to drive pigment loss. There is new evidence that microbes can impact the process of depigmentation, both positively and negatively. Studies are performed in patients to associate disease activity with the microbiome of the skin and gut, and we can use model of disease to evaluate how best to impact the microbiome in our favor, including dietary factors and means to entice regulatory T cells to limit disease. Diet, microbes, T cells, the latest on vitiligo and its management."

Additionally, **David Rosmarin, MD**, will be holding a number of sessions, including "What's New in Development for Vitiligo?" Here, you will be sure to get a rundown of the most viable JAK inhibitors currently available for this disorder. Additionally, says Rosmarin, "We'll discuss novel strategies, including IL-2 agonism to increase T-regulatory cells and anti-IL15 biologics to target skin resident memory T-cells."

And, at **RAA**, **Andrew G. Messenger, MD, FRCP**, will be leading a lively discussion on "Epidemiology of Alopecia Areata." Says Messenger, "How common is alopecia areata? Is its incidence changing as has been reported for other autoimmune diseases? What can we learn about the pathogenesis from the epidemiology? Are there differences in the frequency of alopecia areata between population groups and why? This talk will aim to cover these questions as well as how the epidemiology may impact treatment."